RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.

Hdl Handle:
RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.
Ahlquist, Terje; Bottillo, Irene; Danielsen, Stine A; Meling, Gunn I; Rognum, Torleiv O; Lind, Guro E; Dallapiccola, Bruno; Lothe, Ragnhild A
Neoplasia (New York, N.Y.) 2008, 10 (7):680-6, 2 p following 686
Additional Links:

Full metadata record

DC FieldValue Language
dc.contributor.authorAhlquist, Terje-
dc.contributor.authorBottillo, Irene-
dc.contributor.authorDanielsen, Stine A-
dc.contributor.authorMeling, Gunn I-
dc.contributor.authorRognum, Torleiv O-
dc.contributor.authorLind, Guro E-
dc.contributor.authorDallapiccola, Bruno-
dc.contributor.authorLothe, Ragnhild A-
dc.identifier.citationNeoplasia (New York, N.Y.) 2008, 10 (7):680-6, 2 p following 686en
dc.description.abstractMore than half of all colorectal carcinomas are known to exhibit an activated mitogen-activated protein kinase pathway. The NF1 gene, a negative regulator of KRAS, has not previously been examined in a series of colorectal cancer. In the present study, primary colorectal carcinomas stratified according to microsatellite instability status were analyzed. The whole coding region of NF1 was analyzed for mutations using denaturing high-performance liquid chromatography and sequencing, and the copy number alterations of NF1 were examined using multiple ligation-dependent probe amplification and real-time polymerase chain reaction. The mutational hot spots in KRAS and BRAF were sequenced, and promoter hypermethylation status of RASSF1A was assessed with a methylation-specific polymerase chain reaction. One sample had two missense mutations in NF1, whereas nine additional tumors had intronic mutations likely to affect exon splicing. Interestingly, 8 of these 10 tumors were microsatellite-unstable. Four other tumors showed a duplication of NF1. Mutations in KRAS and BRAF were mutually exclusive and were present at 40% and 22%, respectively. RASSF1A was hypermethylated in 31% of the samples. We show that the RAS signaling network is extensively dysregulated in colorectal carcinomas, because more than 70% of the tumors had an alteration in one or more of the four examined components.en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.subject.meshAged, 80 and overen
dc.subject.meshBase Sequenceen
dc.subject.meshColorectal Neoplasmsen
dc.subject.meshDNA Mutational Analysisen
dc.subject.meshGene Expression Regulation, Neoplasticen
dc.subject.meshGene Regulatory Networksen
dc.subject.meshGenes, Neurofibromatosis 1en
dc.subject.meshGenes, rasen
dc.subject.meshGenetic Screeningen
dc.subject.meshMiddle Ageden
dc.subject.meshModels, Biologicalen
dc.subject.meshSignal Transductionen
dc.subject.meshTumor Suppressor Proteinsen
dc.subject.meshraf Kinasesen
dc.titleRAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.en
dc.typeJournal articleen
dc.typepeer revieweden
dc.contributor.departmentDepartment of Cancer Prevention, Institute for Cancer Research, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway.en
dc.identifier.journalNeoplasia (New York, N.Y.)en
All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.